アブカムでは最適な動作のために Google Chrome など最新ブラウザでの閲覧を推奨します。
Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors. TRAIL/Apo2L is a new member of the TNF family and induces apoptosis of a variety of tumour cell lines. DR4 and DR5 are the recently identified functional receptors for TRAIL (1-3). Two decoy-receptors for TRAIL have been identified and designated DcR1/TRID/TRAIL-R3/LIT and DcR2/TRAIL-R4/TRUNDD. DcR1 has extracellular TRAIL-binding domain but lacks intracellular signaling domain. It is a glycophospholipid-anchored cell surface protein. DcR1 transcripts were expressed in many normal human tissues but not in most cancer cell lines. Overexpression of DcR1 did not induce apoptosis, but attenuated TRAIL-induced apoptosis.
Our Abpromise guarantee covers the use of ab2087 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||Use a concentration of 10 µg/ml.|
|WB||Use a concentration of 0.5 - 1 µg/ml. Predicted molecular weight: 65 kDa.Can be blocked with DcR1 peptide (ab6096). Can be blocked with DcR1 peptide (human).|
Western blot analysis of DcR1 in HeLa cell (A), mouse (B) and rat (C) liver tissue lysates with anti-DcR1 (ED2) at 1
ab2087 at 10µg/ml staining DcR1 in rat liver tissue by ICC/IF
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"